← Eichor
Study identifier: NCT07709858 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement

Condition: Aortic Valve Stenosis · Transcatheter Aortic Valve Replacement (TAVR)  ·  Sponsor: Eunpyeong St. Mary's Hospital

PhaseN/A
Planned participants4000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is a multicenter, retrospective registry study using the CHATEAU Registry. The study will evaluate patients who underwent transcatheter aortic valve replacement between January 2021 and December 2025. The purpose of the study is to assess clinical outcomes and valve performance after TAVR in real-world practice, with a focus on procedural strategies, valve-related factors, and long-term outcomes. Patient clinical information, imaging findings, procedural data, echocardiographic results, and follow-up outcomes will be collected from existing medical records. No additional intervention, treatment, or study-specific visit will be performed.

This description comes directly from the study's public registry record.

Talk to the study team

Osung Kwon, MD. PhD  ·  +821037085673  ·  oscaesar@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Catholic University of Korea, Eunpyeong St. Mary's HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07709858